Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice

BMC Cancer

Liu Zheng¹  Zhang Weilun¹  Jiang Minghong¹  Zhang Yaxi¹  Liu Shilian¹  Liu Yanxin¹  Zheng Dexian¹ 

[1] National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, 5 Dong Dan San Tiao, Beijing, 100005, China

关键词: Gene therapy;    Adeno-associated virus;    TRAIL;    Tet-On;    Controllable gene expression;   

Others  :  1080454
DOI  :  10.1186/1471-2407-12-153

 received in 2011-11-07, accepted in 2012-04-24,  发布年份 2012

【 摘 要 】

Background

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) functions as a cytokine to selectively kill various cancer cells without toxicity to most normal cells. Numerous studies have demonstrated the potential use of recombinant soluble TRAIL as a cancer therapeutic agent. We have showed previous administration of a recombinant adeno-associated virus (rAAV) vector expressing soluble TRAIL results in an efficient suppression of human tumor growth in nude mice. In the present study, we introduced Tet-On gene expression system into the rAAV vector to control the soluble TRAIL expression and evaluate the efficiency of the system in cancer gene therapy.

Methods

Controllability of the Tet-On system was determined by luciferase activity assay, and Western blotting and enzyme-linked immunoabsorbent assay. Cell viability was determined by MTT assay. The breast cancer xenograft animal model was established and recombinant virus was administrated through tail vein injection to evaluate the tumoricidal activity.

Results

The expression of soluble TRAIL could be strictly controlled by the Tet-On system in both normal and cancer cells. Transduction of human cancer cell lines with rAAV-TRE-TRAIL&rAAV-Tet-On under the presence of inducer doxycycline resulted in a considerable cell death by apoptosis. Intravenous injection of the recombinant virus efficiently suppressed the growth of human breast carcinoma in nude mice when activated by doxycycline.

Conclusion

These data suggest that rAAV-mediated soluble TRAIL expression under the control of the Tet-On system is a promising strategy for breast cancer therapy.

【 授权许可】

   
2012 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, et al.: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999, 5(2):157-163.
• [2]Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, et al.: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999, 104(2):155-162.
• [3]Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL: Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000, 165(5):2886-2894.
• [4]Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, et al.: Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res 2003, 63(10):2369-2372.
• [5]Carlo-Stella C, Lavazza C, Di Nicola M, Cleris L, Longoni P, et al.: Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand. Hum Gene Ther. 2006, 17(12):1225-1240.
• [6]Dong F, Wang L, Davis JJ, Hu W, Zhang L, et al.: Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res 2006, 12(17):5224-5230.
• [7]Griffith TS, Broghammer EL: Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol Ther 2001, 4(3):257-266.
• [8]Kagawa S, He C, Gu J, Koch P, Rha SJ, et al.: Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res 2001, 61(8):3330-3338.
• [9]Kock N, Kasmieh R, Weissleder R, Shah K: Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 2007, 9(5):435-442.
• [10]Lee J, Hampl M, Albert P, Fine HA: Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector. Neoplasia 2002, 4(4):312-323.
• [11]Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, et al.: Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med. 2007, 9(6):440-451.
• [12]Seol JY, Park KH, Hwang CI, Park WY, Yoo CG, et al.: Adenovirus-TRAIL can overcome TRAIL resistance and induce a bystander effect. Cancer Gene Ther. 2003, 10(7):540-548.
• [13]Voelkel-Johnson C, King DL, Norris JS: Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002, 9(2):164-172.
• [14]Wenger T, Mattern J, Haas TL, Sprick MR, Walczak H, et al.: Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and -independent effects. Cancer Gene Ther. 2007, 14(3):316-326.
• [15]Yang F, Shi P, Xi X, Yi S, Li H, et al.: Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC). Med Oncol. 2006, 23(2):191-204.
• [16]Zhang Y, Ma H, Zhang J, Liu S, Liu Y, et al.: AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci 2008, 82(23–24):1154-1161.
• [17]Ma H, Liu Y, Liu S, Xu R, Zheng D: Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. Hepatology 2005, 42(6):1355-1363.
• [18]Shi J, Zheng D, Liu Y, Sham MH, Tam P, et al.: Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005, 65(5):1687-1692.
• [19]Ma H, Liu Y, Liu S, Kung HF, Sun X, et al.: Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int J Cancer 2005, 116(2):314-321.
• [20]Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, et al.: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 2000, 6(5):564-567.
• [21]Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, et al.: Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000, 60(3):553-559.
• [22]Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, et al.: Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000, 356(9232):827-828.
• [23]Nesterov A, Ivashchenko Y, Kraft AS: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 2002, 21(7):1135-1140.
• [24]Renshaw SA, Parmar JS, Singleton V, Rowe SJ, Dockrell DH, et al.: Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 2003, 170(2):1027-1033.
• [25]Schaefer U, Voloshanenko O, Willen D, Walczak H: TRAIL: a multifunctional cytokine. Front Biosci 2007, 12:3813-3824.
• [26]Thorburn A: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling. J Thorac Oncol 2007, 2(6):461-465.
• [27]Tang W, Wang W, Zhang Y, Liu S, Liu Y, et al.: Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. FEBS J 2009, 276(2):581-593.
• [28]Tang W, Wang W, Zhang Y, Liu S, Liu Y, et al.: TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner. Cell Res. 2009, 19(6):758-767.
• [29]Kahraman A, Barreyro FJ, Bronk SF, Werneburg NW, Mott JL, et al.: TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology 2008.
• [30]Goverdhana S, Puntel M, Xiong W, Zirger JM, Barcia C, et al.: Regulatable gene expression systems for gene therapy applications: progress and future challenges. Mol Ther 2005, 12(2):189-211.